• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Sensata Announces New Chief Financial Officer

    10/31/23 5:55:00 AM ET
    $PODD
    $ST
    Medical/Dental Instruments
    Health Care
    Industrial Machinery/Components
    Industrials
    Get the next $PODD alert in real time by email
    • Brian Roberts joins Sensata as Executive Vice President and Chief Financial Officer
    • Paul Vasington to retire from Sensata after nearly 10 years as CFO

    Sensata Technologies (NYSE:ST), a global industrial technology company and leading provider of sensors, sensor-rich solutions and electrical protection devices, announced that Brian K. Roberts has been named as Sensata's new CFO, beginning immediately following the filing of the 10-Q for the third quarter 2023 in early November. Brian will assume leadership and oversight of all global financial activities of Sensata.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231031723327/en/

    (Photo: Business Wire)

    (Photo: Business Wire)

    Brian will succeed Sensata's current Chief Financial Officer, Paul Vasington, who has decided to retire from the Company. Paul will remain with Sensata through a transition period and will remain as an advisor to Jeff Cote and Brian until April 2, 2024.

    "I am excited to welcome Brian to Team Sensata," said Jeff Cote, Chief Executive Officer and President. "Brian's 30 years of finance and leadership experience will serve us well as we focus on strong and disciplined execution, margin expansion and debt reduction. Brian will be a critical leader for us as we continue along our transformation journey to become the driving force toward an electrified world and a sustainable future."

    Brian boasts decades of finance, operational and leadership experience across several industries, including marketing and technology services, medical device manufacturing, and life sciences. Most recently, Brian was the Chief Executive Officer of Tarveda Therapeutics, a private venture backed oncology company, which he joined initially as CFO in 2018. Brian has extensive public company operating experience including as CFO at both Insulet Corporation (NASDAQ:PODD), a high-growth medical technology business and Digitas, Inc., through its successful acquisition by Publicis Groupe. Brian also has significant public Board experience including serving for eight years as Audit Committee Chair for ViewRay, Inc.

    Brian started his career at Ernst & Young and is a Certified Public Accountant. He holds a Bachelor of Science in Accounting and Finance from Boston College.

    "On behalf of our Board of Directors and everyone at Sensata, I want to thank Paul for his many years of service and dedication to our company, during a time of extensive change and disruption and wish him well on his well-earned retirement," said Cote. "Paul has built a strong finance team that I am confident will continue to thrive under Brian's leadership."

    Conference Call and Webcast

    Sensata will conduct a conference call today at 8:00 a.m. Eastern Time to discuss its third quarter 2023 financial results and its outlook for the fourth quarter of 2023. The webcast and subsequent replay will be available on the investor relations page of the Company's website at http://investors.sensata.com. Investors can also listen to the earnings call live via telephone by dialing 1-844-784-1726 or 1-412-380-7411 and referencing the Sensata Q3 2023 Financial Results Conference Call. A replay of the call will be available until November 7, 2023. To access the replay dial 1-877-344-7529 or 1-412-317-0088 and enter confirmation code: 1055825.

    About Sensata Technologies

    Sensata Technologies is a global industrial technology company striving to create a cleaner, more efficient, electrified, and connected world. Through its broad portfolio of sensors, electrical protection components and sensor-rich solutions which create valuable business insights, Sensata helps its customers address increasingly complex engineering and operating performance requirements. With more than 21,000 employees and global operations in 16 countries, Sensata serves customers in the automotive, heavy vehicle & off-road, industrial, and aerospace markets. Learn more at www.sensata.com and follow us on LinkedIn, Facebook and Twitter.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20231031723327/en/

    Get the next $PODD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PODD
    $ST

    CompanyDatePrice TargetRatingAnalyst
    Insulet Corporation
    $PODD
    1/27/2026$294.00Hold
    TD Cowen
    Insulet Corporation
    $PODD
    1/12/2026$274.00Overweight → Equal Weight
    Barclays
    Insulet Corporation
    $PODD
    12/16/2025$370.00Outperform
    Evercore ISI
    Insulet Corporation
    $PODD
    11/19/2025$400.00Neutral → Buy
    UBS
    Insulet Corporation
    $PODD
    10/21/2025$370.00Buy
    Stifel
    Sensata Technologies Holding plc
    $ST
    10/8/2025$43.00Overweight
    Barclays
    Insulet Corporation
    $PODD
    9/8/2025$365.00Outperform
    Oppenheimer
    Insulet Corporation
    $PODD
    6/16/2025$365.00Buy
    Truist
    More analyst ratings

    $PODD
    $ST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen resumed coverage on Insulet with a new price target

    TD Cowen resumed coverage of Insulet with a rating of Hold and set a new price target of $294.00

    1/27/26 8:46:58 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet downgraded by Barclays with a new price target

    Barclays downgraded Insulet from Overweight to Equal Weight and set a new price target of $274.00

    1/12/26 8:59:23 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Evercore ISI initiated coverage on Insulet with a new price target

    Evercore ISI initiated coverage of Insulet with a rating of Outperform and set a new price target of $370.00

    12/16/25 9:28:48 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $PODD
    $ST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Chief HR Officer Caljouw Lynne J sold $93,675 worth of Ordinary Shares (2,496 units at $37.53), decreasing direct ownership by 4% to 64,040 units (SEC Form 4)

    4 - Sensata Technologies Holding plc (0001477294) (Issuer)

    2/17/26 6:39:39 PM ET
    $ST
    Industrial Machinery/Components
    Industrials

    SVP, Global Operations Singh Prem was granted 2,532 shares and covered exercise/tax liability with 861 shares, increasing direct ownership by 48% to 5,158 units (SEC Form 4)

    4 - INSULET CORP (0001145197) (Issuer)

    2/17/26 5:27:20 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    SVP and General Counsel Kapples John W. was granted 5,246 shares and covered exercise/tax liability with 1,929 shares, increasing direct ownership by 14% to 26,497 units (SEC Form 4)

    4 - INSULET CORP (0001145197) (Issuer)

    2/17/26 5:26:12 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $PODD
    $ST
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Stonesifer Timothy C. bought $299,884 worth of shares (962 units at $311.73), increasing direct ownership by 27% to 4,591 units (SEC Form 4)

    4 - INSULET CORP (0001145197) (Issuer)

    12/8/25 4:02:55 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Director Teich Andrew C bought $250,011 worth of Ordinary Shares (9,925 units at $25.19), increasing direct ownership by 32% to 41,117 units (SEC Form 4)

    4 - Sensata Technologies Holding plc (0001477294) (Issuer)

    5/28/25 4:10:06 PM ET
    $ST
    Industrial Machinery/Components
    Industrials

    EVP, CFO & Treasurer Chadwick Ana Maria bought $20,600 worth of shares (100 units at $206.00), increasing direct ownership by 0.76% to 13,314 units (SEC Form 4)

    4 - INSULET CORP (0001145197) (Issuer)

    8/29/24 4:17:26 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $PODD
    $ST
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sensata Technologies Reports Fourth Quarter and Full Year 2025 Financial Results

    Sensata Technologies (NYSE:ST) today announced financial results for its fourth quarter and full year ended December 31, 2025. "With our Q4 and Full Year 2025 results, I am pleased to report that we delivered on our objectives for the first year of our transformation journey. We expanded margins sequentially each quarter this year, dramatically improved free cash flow, strengthened our balance sheet, and, in the fourth quarter, we returned to year-over-year revenue growth," said Stephan von Schuckmann, Sensata's Chief Executive Officer. "As we look ahead to 2026 and beyond, we are now a more resilient organization, and we have a solid foundation on which to build. I am confident that with

    2/19/26 4:05:00 PM ET
    $ST
    Industrial Machinery/Components
    Industrials

    Insulet Reports Fourth Quarter and Full Year 2025 Results

    Fourth Quarter 2025 Revenue Increase of 31% (29% Constant Currency1) and Full Year 2025 Revenue Increase of 31% Year-Over-Year (30% Constant Currency) Represents 10th Consecutive Year of 20% or More Constant Currency Revenue Growth Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months and full year ended December 31, 2025. Fourth Quarter Financial Highlights: Revenue of $783.8 million, up 31.2%, or 29.0% in constant currency, and exceeded the high end of the Company's guidance range of 25% to 28% in constant currency Total Omnipod

    2/18/26 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet Launches Omnipod® 5 and Omnipod Discover™ in the Middle East to Transform Diabetes Care

    The Omnipod 5 Automated Insulin Delivery System is now commercially available in Saudi Arabia, Kuwait, Qatar, and the United Arab Emirates, compatible with Abbott and Dexcom continuous glucose sensors Inaugural launch of Omnipod Discover data management platform aims to lessen the burdens on healthcare providers and users, streamlining diabetes information into meaningful insights Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its transformative Omnipod 5 Automated Insulin Delivery (AID) System is now available in the Middle East – including Saudi Arabia, Kuwait, Q

    2/5/26 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $PODD
    $ST
    SEC Filings

    View All

    Sensata Technologies Holding plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Sensata Technologies Holding plc (0001477294) (Filer)

    2/19/26 4:11:09 PM ET
    $ST
    Industrial Machinery/Components
    Industrials

    SEC Form 10-K filed by Insulet Corporation

    10-K - INSULET CORP (0001145197) (Filer)

    2/18/26 4:03:03 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - INSULET CORP (0001145197) (Filer)

    2/18/26 7:05:33 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $PODD
    $ST
    Leadership Updates

    Live Leadership Updates

    View All

    Insulet Announces Appointment of Robert L. Huffines to its Board of Directors

    Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the appointment of Robert ("Robbie") L. Huffines, a former Global Chair of Investment Banking at JP Morgan Chase & Co., to the Company's board of directors, effective October 31, 2025. Mr. Huffines joins the board as an independent director and will serve on the board's Audit Committee. "We are honored to welcome Robbie to Insulet's Board of Directors," said Timothy Scannell, Chairman of the Board. "Robbie brings more than three decades of distinguished experience advising healthcare companies at one of the world's leading f

    10/23/25 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet to Host Investor Day on November 20, 2025

    Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, will host an Investor Day at the Company's Acton, Massachusetts headquarters on Thursday, November 20, 2025. The Investor Day will include presentations from the management team highlighting the Company's longer-term strategic priorities, including market opportunities, innovation roadmap, as well as its longer-term financial outlook. Manufacturing tours will be available following the conclusion of the formal presentations, which are expected to begin at 9:00 a.m. (ET) and conclude at approximately 12:30 p.m. (ET). The Company invites in

    10/10/25 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet Announces CFO Transition

    Flavia Pease Appointed Chief Financial Officer Insulet Corporation (NASDAQ:PODD) ("Insulet" or the "Company"), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that Flavia Pease will succeed Ana Maria Chadwick as Executive Vice President, Chief Financial Officer, effective September 30, 2025. Ms. Chadwick will become a Senior Advisor to Insulet to ensure a smooth transition. "I want to personally thank Ana, who has provided steady and thoughtful leadership for Insulet during a period of significant growth," said Ashley McEvoy, Insulet President and Chief Executive Officer. "She has been instrumental in strengthening our financial

    9/16/25 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $PODD
    $ST
    Financials

    Live finance-specific insights

    View All

    Sensata Technologies Reports Fourth Quarter and Full Year 2025 Financial Results

    Sensata Technologies (NYSE:ST) today announced financial results for its fourth quarter and full year ended December 31, 2025. "With our Q4 and Full Year 2025 results, I am pleased to report that we delivered on our objectives for the first year of our transformation journey. We expanded margins sequentially each quarter this year, dramatically improved free cash flow, strengthened our balance sheet, and, in the fourth quarter, we returned to year-over-year revenue growth," said Stephan von Schuckmann, Sensata's Chief Executive Officer. "As we look ahead to 2026 and beyond, we are now a more resilient organization, and we have a solid foundation on which to build. I am confident that with

    2/19/26 4:05:00 PM ET
    $ST
    Industrial Machinery/Components
    Industrials

    Insulet Reports Fourth Quarter and Full Year 2025 Results

    Fourth Quarter 2025 Revenue Increase of 31% (29% Constant Currency1) and Full Year 2025 Revenue Increase of 31% Year-Over-Year (30% Constant Currency) Represents 10th Consecutive Year of 20% or More Constant Currency Revenue Growth Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months and full year ended December 31, 2025. Fourth Quarter Financial Highlights: Revenue of $783.8 million, up 31.2%, or 29.0% in constant currency, and exceeded the high end of the Company's guidance range of 25% to 28% in constant currency Total Omnipod

    2/18/26 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Sensata Technologies Board Approves Q1 2026 Dividend of $0.12 per share

    Sensata Technologies (NYSE:ST) today announced that its Board of Directors approved a quarterly dividend in the amount of $0.12 per share. The Company will pay this first quarter 2026 dividend on February 25, 2026, to shareholders of record as of February 11, 2026. About Sensata Technologies Sensata Technologies is a global industrial technology company striving to create a safer, cleaner, more efficient and electrified world. Through its broad portfolio of mission-critical sensors, electrical protection components and sensor-rich solutions, Sensata helps its customers address increasingly complex engineering and operating performance requirements. With more than 18,000 employees and gl

    1/28/26 4:30:00 PM ET
    $ST
    Industrial Machinery/Components
    Industrials

    $PODD
    $ST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sensata Technologies Holding plc

    SC 13G/A - Sensata Technologies Holding plc (0001477294) (Subject)

    11/14/24 3:09:46 PM ET
    $ST
    Industrial Machinery/Components
    Industrials

    Amendment: SEC Form SC 13G/A filed by Insulet Corporation

    SC 13G/A - INSULET CORP (0001145197) (Subject)

    11/12/24 12:53:28 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sensata Technologies Holding plc

    SC 13G/A - Sensata Technologies Holding plc (0001477294) (Subject)

    11/12/24 9:44:56 AM ET
    $ST
    Industrial Machinery/Components
    Industrials